New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:20 EDTICPTIntercept data should be positive catalyst for shares, says Oppenheimer
Oppenheimer predicts that top-line data for Intercept's Phase 2 FLINT study in NASH, expected to be released in July, will be a positive catalyst for the stock. The firm thinks that the risk/reward ratio for the stock heading into the data release should be attractive as long as expectations remain modest. It keeps a $499 price target and Outperform rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
07:11 EDTICPTIntercept announces NDA for OCA accepted for review by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use